Combining biologic therapieswith other systemic treatments in psoriasis: Evidence-based, best-practice recommendations from the medical board of the national psoriasis foundation

JAMA Dermatology

Volumn 151, Issue 4, 2015, Pages 432-438

  Armstrong, April W ^a   Bagel, Jerry ^b   Van Voorhees, Abby S ^c   Robertson, Andrew D ^d   Yamauchi, Paul S ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b School of Medicine ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d National Psoriasis Foundation   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; DERMATOLOGICAL AGENT;

BIOLOGICAL THERAPY; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; MONOTHERAPY; PATIENT SELECTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; ULTRAVIOLET B RADIATION; COMPARATIVE STUDY; DRUG COMBINATION; EVIDENCE BASED MEDICINE; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; PHOTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84928248645     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.3456     Document Type: Review

References (50)

1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16-17.
2. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935. doi:10.1371/journal.pone.0052935.
3. Stern RS; PUVA Follow-up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J AmAcad Dermatol. 2012;66(4):553-562.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 5: guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J AmAcad Dermatol. 2010;62(1):114-135.
5. Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162(5):952-963.
6. Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW. Combination treatments for psoriasis: a systematic review and meta-analysis. Arch Dermatol. 2012;148(4):511-522.
7. Famenini S, Wu JJ. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment. Cutis. 2013;92(3):140-147.
8. Ozdemir M, Engin B, Baysal I, Mevlitoʇlu I. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. Acta Derm Venereol. 2008;88(6):589-593.
9. Lauharanta J, Juvakoski T, Lassus A. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol. 1981;104(3):325-332.
10. Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol. 1989;121(1):107-112.
11. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica. 1988;177(4):218-224.
12. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126(4):482-486.
13. Tanew A, Guggenbichler A, Hönigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4):682-684.
14. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120(2):211-216.
15. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol. 2003;49(2) (suppl):S118-S124.
16. Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144(1):97-99.
17. Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. 2011;164(6):1383-1386.
18. Park KK, Wu JJ, Koo J. A randomized, "head-to-head" pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol. 2013;27(7):899-906.
19. Wolf P, Hofer A, Weger W, Posch-Fabian T, Gruber-Wackernagel A, Legat FJ. 311 nm Ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27(4):186-189.
20. Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166(1):147-153.
21. Kircik L, Bagel J, Korman N, et al; UNITE Study Group. Utilization of Narrow-band Ultraviolet Light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol. 2008;7(3):245-253.
22. De Simone C, D'Agostino M, Capizzi R, Capponi A, Venier A, Caldarola G. Combined treatment with etanercept 50mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol. 2011;21(4):568-572.
23. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol. 2009;160(1):186-189.
24. Lynde CW, Gupta AK, Guenther L, Poulin Y, Levesque A, Bissonnette R. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23(4):261-267.
25. Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis. J Drugs Dermatol. 2011;10(4):366-371.
26. Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495-501.
27. Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649-657.
28. Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol. 2009;23(3):277-282.
29. Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008;159(2):460-463.
30. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther. 2004;6(4):R326-R334.
31. Kavanaugh A, Krueger GG, Beutler A, et al; IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66(4):498-505.
32. De Groot M, Teunissen MB, Picavet DI, et al. Adalimumab in combination with methotrexate more effectively reduces the numbers of different inflammatory cell types in lesional psoriatic skin than does single treatment with adalimumab or methotrexate. Br J Dermatol. 2008;158(6):1401.
33. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127-132.
34. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345-1349.
35. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008;47(5):514-518.
36. Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J AmAcad Dermatol. 2006;54(3) (suppl 2):S135-S138.
37. Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol. 2010;22(2):138-142.
38. Gattu S, Wu J, Koo J. Can adalimumab make a smooth and easy transition from cyclosporine a reality? a case series of successful transitions. Psoriasis Forum. 2009;15(2):33-35.
39. Bernardo S, Geraghty L, Freilich A, Pan M, Lebwohl M. Frequency of monotherapy vs combination therapy in reported cases of infections occurring in the setting of biologic agents. Psoriasis Forum. 2013;19(1):2-15. https://www.psoriasis.org/files/publications/forum/Forum-SPRING-2013.pdf. Accessed October 6, 2014.
40. Bernardo S, Harcharik S, Pan M, Keeley B, Lebwohl M. Biologic drugs and malignancy: a literature review examining the impact of concomitant immunosuppressive medications. Psoriasis Forum. 2012;18(4):152-163.
41. Greenberg JD, Reed G, Kremer JM, et al; CORRONA Investigators. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69(2):380-386.
42. Booij MT, Van De Kerkhof PC. Acitretin revisited in the era of biologics. J Dermatolog Treat. 2011;22(2):86-89.
43. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology, part I. J AmAcad Dermatol. 2010;63(6):925-948.
44. Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. 2005;5:9.
45. Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J Drugs Dermatol. 2008;7(11):1089-1093.
46. Adişen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin Exp Dermatol. 2008;33(2):164-166.
47. Kitamura G, Mehr N, Anderson N, Sirichotiratana M. A case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J. 2009;15(2):11.
48. Cuchacovich R, Garcia-Valladares I, Espinoza LR. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol. 2012;39(1):187-193.
49. Heinecke GM, Luber AJ, Levitt JO, Lebwohl MG. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol. 2013;12(10):1098-1102.
50. Krell JM. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J AmAcad Dermatol. 2006;54(6):1099-1101.